- Posts:
- 0 (0 per day)
- Age:
- N/A
- Date Registered:
- May 02, 2024, 03:12:19 PM
- Local Time:
- May 18, 2024, 11:07:54 AM
- Last Active:
- May 02, 2024, 06:50:01 PM
Signature:
3% compared to. 30.7%) but not using infarction as well as cerebral hemorrhage. Bottom line Anlotinib may benefit sufferers using superior NSCLC with